Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

45.94 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 310,101
Open 45.94
Bid (Size) 46.71 (200)
Ask (Size) 46.72 (200)
Prev. Close 45.94
Today's Range 45.94 - 45.94
52wk Range 45.05 - 112.52
Shares Outstanding N/A
Dividend Yield 4.78%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs. 
Via The Motley Fool
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government

Performance

YTD
-47.5%
-47.5%
1 Month
-20.1%
-20.1%
3 Month
-7.9%
-7.9%
6 Month
-32.2%
-32.2%
1 Year
-57.9%
-57.9%

More News

Read More
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion
Via Investor's Business Daily
Topics Initial Public Offering
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices
Via Stocktwits
Topics Government
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith
Via Stocktwits
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump
Via The Motley Fool
Topics World Trade
Should You Buy Novo Nordisk After the Huge Investor Update?
Via The Motley Fool
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Via The Motley Fool
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.
Via The Motley Fool
Topics Government
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Via Benzinga
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy
Via Benzinga
Why Novo Nordisk Stock Is Sinking This Week
Via The Motley Fool
Topics Government World Trade
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Via Benzinga
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
Via Benzinga
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
Via Investor's Business Daily
Topics Government
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced
Via Stocktwits
Topics Government World Trade
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts
Via Benzinga
Topics Government
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
Via Benzinga
Topics Government
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Via The Motley Fool
Topics Earnings
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo
Via Investor's Business Daily
Topics Government
Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits
Via Benzinga
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Via Benzinga

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 45.94
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 11/10/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.